Core Viewpoint - Garden Bio reported a slight decline in revenue but an increase in net profit and cash flow, indicating improved operational quality and cash collection ability [1] Financial Performance - The company achieved a revenue of 300 million yuan in the first three quarters, a year-on-year decrease of 0.2% [1] - The net profit attributable to shareholders, excluding non-recurring gains and losses, was 72 million yuan, reflecting a year-on-year growth of 9.06% [1] - Total assets reached 5.913 billion yuan, up 5.36% year-on-year [1] - The net cash flow from operating activities was 345 million yuan, an increase of 27.02% year-on-year [1] Business Strategy - The company focuses on two main areas: Vitamin D3 and pharmaceutical manufacturing, implementing a "vertical and horizontal" development strategy [1] - The "vertical" strategy consolidates its advantages in the Vitamin D3 supply chain while entering pharmaceutical manufacturing through the acquisition of Garden Pharmaceuticals [1] - The "horizontal" strategy aims to expand the product line into new varieties such as Vitamins A, E, B6, and biotin, positioning the company as a comprehensive vitamin giant [1] Research and Development - The company has established three R&D centers in Dongyang, Jinhua, and Hangzhou, focusing on natural product biosynthesis, industrial research, and cutting-edge drug trials [2] - Garden Pharmaceuticals has a dedicated R&D center aimed at developing new products and optimizing existing processes to enhance core competitiveness [2] - The company has developed a unique vertical integration advantage by self-producing NF-grade cholesterol and extending into the pharmaceutical health product sector [3] Product Development and Market Position - The company has completed the construction of a 6,000-ton VA powder project and is preparing for trial production of a 5,000-ton VB6 project and a 200-ton biotin project [3] - Garden Pharmaceuticals is strategically selecting products for development based on clinical supply shortages and market potential, focusing on chronic diseases such as hypertension and respiratory diseases [3] - The company has obtained drug registration certificates for 10 products, with several included in national and local centralized procurement, enhancing sales channels [4] Industry Outlook - The company is positioned within strategic concepts like "new quality productivity" and "synthetic biology," which are expected to bring policy support and long-term growth potential [4]

Core Insights - Vitamin B12, also known as cobalamin, is essential for human health, playing a critical role in nerve function and preventing pernicious anemia. It is used in the treatment of various diseases such as cerebral hemorrhage, Alzheimer's disease, and acute myelitis. The market demand for Vitamin B12 supplements is increasing due to rising health awareness among consumers. The market size of the cobalamin industry in China is projected to reach 1.4 billion yuan in 2024, representing a year-on-year growth of 6% [1][10]. Industry Overview - Cobalamin, or Vitamin B12, is the only vitamin that contains a metal element. It is a red crystalline powder that is water-soluble and plays multiple indispensable roles in the human body, including maintaining a healthy nervous system and promoting red blood cell production [3][10]. - The primary sources of Vitamin B12 are animal products, with some plant sources like soybeans containing lower amounts. The vitamin is crucial for protein and amino acid synthesis, especially in infants [3]. Market Dynamics - China is a major supplier of Vitamin B12 globally, with significant export volumes. The export quantity of unblended Vitamin B12 and its derivatives is expected to grow from 355.08 tons in 2020 to 498.08 tons by 2024 [10]. - The competition in the cobalamin market is intensifying due to limited market size and high domestic production capacity. Major players include Hebei Huaron, Yuxing Bio, Ningxia Jinyi, and Jiutian Pharmaceutical [10][11]. Production Methods - The cobalamin industry primarily utilizes microbial fermentation methods for production, as chemical synthesis is complex and costly. The fermentation process mainly involves anaerobic fermentation using Propionibacterium and aerobic fermentation using Pseudomonas [8]. Industry Trends - The cobalamin industry is expected to see continuous technological innovation, focusing on refining extraction methods and enhancing product stability. The use of biotechnological advancements will likely lead to higher activity and lower impurity levels in cobalamin products [12]. - There is a trend towards high-end and diversified product offerings to meet varying consumer needs, including specialized products for anemia treatment and a wider range of dosage forms [13]. - The industry is moving towards environmentally sustainable practices, including green sourcing of raw materials and energy-efficient extraction processes [14].

Summary of the Conference Call Company and Industry Overview - The conference call focuses on the vitamin industry, particularly the role of vitamins in animal nutrition and the performance of the company Xinhecheng in this sector [2][12][18]. Key Points and Arguments Vitamin Demand in Animal Nutrition - Industrialized farming relies heavily on vitamin additives, with feed demand accounting for approximately 60%, and certain vitamins like A and D3 reaching up to 80% [2][5]. - In 2022, pig and poultry feed constituted 86% of China's total feed demand, with pig feed around 45% and poultry feed at 41% [9]. - The profitability of farming significantly influences vitamin demand, with farmers reducing vitamin usage during low-profit periods [9][10]. Market Dynamics and Trends - The vitamin industry has evolved from monopolies by companies like Merck and Roche to increased competition from Japanese firms and Chinese companies like Xinhecheng and Zhejiang Medicine [2][12]. - The global vitamin market currently faces an oversupply, leading companies to halt production to maintain prices [2][13]. - Seasonal demand for animal nutrition supplements peaks in the fourth quarter due to pre-holiday fattening, while summer demand is relatively low [2][14]. Price Fluctuations and Influencing Factors - Vitamin prices are influenced by environmental policies, raw material supply constraints, and unforeseen events [14][15]. - Historical trends show that demand typically sets the price baseline, while supply determines the price ceiling [15]. Xinhecheng's Strategic Positioning - Xinhecheng is diversifying its portfolio beyond vitamins, focusing on amino acids, flavoring agents, and new materials, which have shown strong growth [4][18]. - The company has established a competitive edge in the flavoring market, achieving a gross margin exceeding 50% [19]. - Xinhecheng's new materials business has also seen rapid growth, with products like PPS and PPA reaching global leading levels [20]. Financial Performance and Future Outlook - In 2024, vitamin E prices were at historical highs, significantly contributing to the company's profits, but overall profit impact from vitamin price fluctuations is limited [21]. - The company is expected to continue providing good shareholder returns, including special dividends in profitable years [24]. Market Conditions for Methionine - The market for methionine is stable, with concerns about price impacts from new production capacity being mitigated by steady demand [22][23]. Additional Important Insights - The vitamin market's supply-demand relationship has historically influenced pricing, with significant fluctuations observed during periods of high profitability in the livestock sector [15][16]. - Xinhecheng's long-term growth potential and strong financial metrics make it an attractive option for long-term investors [24].

Group 1 - The company reported a stable performance with revenue of 635 million yuan (up 5.86% year-on-year) and a net profit of 162 million yuan (up 13.67% year-on-year) for the first half of 2025, driven by effective cost control [1] - Vitamin product revenue reached 301 million yuan (up 17.98% year-on-year), while revenue from lanolin and its derivatives grew significantly to 133 million yuan (up 42.12% year-on-year) [1] - The pharmaceutical segment experienced a decline in revenue to 192 million yuan (down 20.30% year-on-year) due to the impact of centralized procurement [1] Group 2 - The company is the only global producer of the full VD3 industrial chain, holding a 70% market share in NF-grade cholesterol, which provides a cost advantage despite falling VD3 prices [2] - New production capacities for vitamin A powder, vitamin B6, and biotin are expected to contribute to future revenue growth [2] - The company has adjusted its revenue forecasts for vitamin products and pharmaceuticals while increasing projections for cholesterol and lanolin derivatives, with expected earnings per share of 0.63, 0.73, and 0.93 yuan for 2025-2027 [2]

Macro Economic Group - The US manufacturing sector continues to contract, with the ISM manufacturing PMI for June at 49, indicating a decline for four consecutive months. New orders index dropped to 46.4, reflecting the largest decrease in three months [3][4] - Manufacturing output returned to expansion at 50.3 in June after three months of contraction, driven by domestic and export orders, although this improvement may be partly due to inventory accumulation in response to rising tariffs [3] - Employment index fell to 45, marking a three-month low, and the price index reached 69.7, indicating ongoing cost pressures for manufacturers [4] Industry Comprehensive Group - The Central Financial Committee's recent meeting emphasized the need for a unified national market and high-quality development of the marine economy, suggesting a potential delay in economic stimulus policies due to better-than-expected economic performance in the first half of the year [7] - The focus on regulating low-price competition among enterprises may enhance market expectations for reduced competition in highly saturated industries and increased policy support for the marine economy, potentially creating investment opportunities [7] Advanced Manufacturing Group - In June, China's heavy truck market saw wholesale sales of 92,000 units, a 4% month-on-month increase and a 29% year-on-year surge, indicating a recovery trend in the industry [10] - Electric heavy trucks have gained significant traction, with sales exceeding 15,000 units in June, representing over a 120% year-on-year growth, and a domestic penetration rate exceeding 24% [10][11] - The demand for heavy trucks is being driven by a vehicle replacement policy, although challenges remain in the freight market, including low prices and tight supply [11] Consumer Group - Jinbo Biological announced a targeted fundraising of 2 billion yuan, with strategic partnerships expected to enhance its market presence and production capabilities in the collagen protein sector [13] - The collaboration with Yangshengtang and the experience of Wan Tai Biological in international markets may facilitate Jinbo Biological's expansion and product commercialization [13]

Investment Rating - The investment rating for the company is maintained as "Buy" [2] Core Views - The prices of the main products, Vitamin B1 and B6, remain strong, contributing to profit growth. The company is a significant supplier in the global B vitamin market, holding leading market shares in Vitamin B6 and B1, with a revenue contribution of 78% from B vitamins in 2024. The prices for Vitamin B6 and B1 have shown year-on-year increases of 43.8% and 21.04% respectively in the first half of 2025, driving rapid profit growth [8][5] - The company is expanding its product line with new projects, including Vitamin B5 and Vitamin A, which are expected to enhance its long-term growth potential. The successful launch of these new products could significantly increase the company's market presence [8] - The financial forecast has been slightly adjusted, with expected net profits for 2025, 2026, and 2027 projected at 921 million, 1,063 million, and 1,070 million respectively. The corresponding PE ratios are estimated at 13, 11, and 11 times. The target market value for 2025 is set at 141 billion, indicating a 21% upside potential from the current market value [8][10] Financial Data and Profit Forecast - Total revenue is projected to grow from 2,209 million in 2024 to 2,708 million in 2025, with a year-on-year growth rate of 22.6%. The net profit is expected to increase from 651 million in 2024 to 921 million in 2025, reflecting a growth rate of 41.4% [7][12] - The gross margin is anticipated to improve from 42% in 2024 to 51.1% in 2025, while the return on equity (ROE) is expected to rise from 14.1% to 16.6% during the same period [7][12]

Group 1: Investor Relations Activity Overview - The investor relations activity was conducted on May 15, 2025, at Chengdu Oukang Pharmaceutical Co., Ltd. [3] - Attendees included representatives from Kaiyuan Securities, Huayuan Securities, Zhongrui Huyin, and Luxin Chuangtou [3] - Company representatives included Chairman Zhao Zhuojun and CFO Cao Yongqiang [3] Group 2: Impact of Industry Trends - The overall price decline in the vitamin industry has limited impact on the company's product pricing, which is primarily influenced by raw material supply and market demand [5] - The company specializes in flavonoid products, a niche within the vitamin sector, using raw materials like bitter orange and sophora flower [5] Group 3: Production Capacity and Utilization - The new plant's production lines for bitter orange are expected to achieve over 50% capacity utilization by the end of 2025 [6] - The production lines for sophora flower are also projected to reach 50% capacity utilization by year-end 2025, with a focus on fine management and market expansion [6] Group 4: Market Expansion and Partnerships - The company has established strong partnerships in Japan for its sophora flower and bitter orange products, focusing on the food additive and health product markets [7] - Ongoing efforts are being made to deepen cooperation with clients and expand market influence in Japan [7] Group 5: Facility Upgrades and Compliance - Upgrades to the Diosmin and Rutin production lines have been completed, meeting both domestic and international GMP standards [8] - The upgraded lines have passed domestic GMP compliance checks and are in the process of obtaining EuGMP certification [8] Group 6: Financial Projections - The company anticipates a 160% increase in depreciation expenses for 2025 compared to 2024 due to the completion of investment projects [9] - Strategies will be implemented to enhance sales revenue to offset increased depreciation costs [9] Group 7: Profitability and Market Trends - The company's gross margin has declined due to production challenges and increased costs in Q1 2025, but is expected to recover as production lines stabilize [11] - The market for quercetin is projected to grow significantly due to rising health awareness and demand for natural ingredients, particularly in health supplements and functional foods [12]

近日， 【SynBioCon】 获 悉，" 维生素的高效异源合成 "是 国家重点研发计划"合成生物学"专项2024年度立项项目，由 四川大学牵头、轻工科学 与工程学院许正宏教授担任项目负责人，4月25日在成都召开 项目启动暨实施方案论证会，会议邀请了 四川大学石碧院士、 四川省科学技术厅陈学华 副厅长、四川大学刘超副校长等多位 领导和行业权威专家 共同研讨项目实施方案。 该项目包含 4个方向 ：" 维生素异源合成途径设计与优化" 、" 关键酶的机理解析与设计改造 "、" 高效异源合成细胞工厂的构建与精准调控 "、" 维 生素绿色智能制造及产业化示范 "。 本次会议的召开标志着"维生素的高效异源合成"项目正式进入全面实施阶段 。项目团队将按照专家意见进一步完善研究方案，加强协同创新，力争在 维生素生物合成领域取得突破性进展，为我国生物制造产业发展贡献力量。 01 热点赛道：维生素+合成生物，国内企业乘势而上 根据其溶解性，维生素分为 水溶性维生素 和 脂溶性维生素 两大类。 脂溶性维生素（ 维生素 A、维生素 D 、维生 素 E 和维生素 K ）具有非常广阔 的市场前景，目前维生素A以及维生素E占有约45%的市 ...